Jean-Paul Castaigne
Directeur/Membre du Conseil chez Tranzyme Pharma, Inc. (Canada)
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| John-Michel Huss | M | 59 |
BioQuebec
 BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | 13 ans |
| Jean-François Pariseau | M | 54 |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Aaron Davidson | M | 55 |
Tranzyme Pharma, Inc. (Canada)
| - |
| Geneviève Guertin | F | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Paul L’Archevêque | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Louise Proulx | M | 73 |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Mario Lebrun | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Gilles Chaumillon | M | 61 |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Glenn Washer | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Frédéric Leduc | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Michel Provence | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Francois-Thomas Mihaud | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | - |
| Benoit Larose | M | - |
BioQuebec
BioQuebec BiotechnologyHealth Technology BioQuebec is the largest biotechnology and life sciences network in Quebec, Canada. The private company is based in Bromont, Canada. BioQuebec's 130 members include companies and organizations that operate at every level of the biotechnology and life sciences innovation chain, ranging from biotechs to pharmas, contract research organizations, venture capital firms, and support organizations. The Canadian company engages in governmental representation, business development, and partnerships to support the growth of Quebec's biotechnology and life sciences industry, which creates wealth and specialized jobs, is focused on innovation and marketing, and is dedicated to improving everyone's health and quality of life. BioQuebec's actions aim to make Quebec one of the industry's most significant and valuable players on the international stage. The company was founded in 1991 by Pierre Alary, and the CEO is Mario Lebrun. | 1 ans |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Jeryl Hilleman | F | 67 | 1 ans | |
| Eckard Weber | M | 73 | - | |
| Sharon Tetlow | F | 64 | - | |
| Yves Mersch | M | - |
Université Paris 1 Panthéon-Sorbonne
| 5 ans |
| Linda Grais | M | 68 | 9 ans | |
| Vipin K. Garg | M | 67 | 13 ans | |
| Jean-Louis Borloo | M | 73 |
Université Paris 1 Panthéon-Sorbonne
| 4 ans |
| George Abercrombie | M | 69 | 2 ans | |
| Gordana Košutic | M | 73 | 6 ans | |
| Franck S. Rousseau | M | 67 | 1 ans | |
| Richard Eisenstadt | M | 66 | 9 ans | |
| Mark E. Kaufmann | M | 56 |
Allostera Pharma, Inc.
 Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 5 ans |
| Rhonda L. Stanley | F | 64 | 4 ans | |
| Lars Ekman | M | 74 | 6 ans | |
| Jean-Claude Stessels | M | - |
Université Paris 1 Panthéon-Sorbonne
| 4 ans |
| Dana S. McGowan | F | - | - | |
| Helmut Thomas | M | 72 | 7 ans | |
| Alan Moore | M | - | 4 ans | |
| Pratik Shah | M | 54 | 9 ans | |
| Michael Powell | M | 69 | 4 ans | |
| Steven James | M | 66 | 3 ans | |
| Nina Kjellson | F | 49 | 4 ans | |
| John Johnson | M | 66 | 3 ans | |
| Anne VanLent | F | 76 | 6 ans | |
| Wendell Wierenga | M | 76 | 4 ans | |
| Christiane Quiniou | M | - |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 ans |
| Sylvain Chemtob | M | - |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 8 ans |
| Brenda D. Gavin | M | 76 | 6 ans | |
| Kenneth Ruettimann | M | - | - | |
| Olivier Aubert | M | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Frédéric Bizière | M | 57 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Corinne M. Saunders | F | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Benoît Hérault | M | 57 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Yi He | M | 70 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Olivier Ceccarelli | M | 61 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Alexandra Soto | F | 55 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Brent Bankosky | M | - | - | |
| François Jean Henri Pinault | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Cyrille Fagué | M | - |
Université Paris 1 Panthéon-Sorbonne
| 1 ans |
| Pierre du Baret | M | 61 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Béatrice Marie Derouvroy-Bernard | F | 61 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Marie-Christine Ducholet | F | 61 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Rajiv Patni | M | 55 | 1 ans | |
| Melchior de Vogüe | M | 62 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Michael Byrnes | M | 47 | 3 ans | |
| Jean-Luc Allavena | M | 60 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Olivier Wigniolle | M | 60 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Gérard Kuperfarb | M | - |
École des Hautes Études Commerciales de Paris
| 1 ans |
| Manuel Ramos de Sousa Sebastião | M | 73 |
Université Paris 1 Panthéon-Sorbonne
| 3 ans |
| Damien Faucher | M | 62 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Kareen Ceintre | M | 61 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Géry Robert-Ambroix | M | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Ghislaine Doukhan | F | 57 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Valérie Hermann | F | 61 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Ela Borenstein | F | - |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | 4 ans |
| Pierre Casamatta | M | 59 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Stéphane Thiroloix | M | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Corinne Pollier-Bousquet | F | 59 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Philippe Schaison | M | 62 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Bogdan Dziurzynski | M | 75 |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
| Anne F. McKay | F | - | - | |
| Olivier Rudigoz | M | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Laurent Mignon | M | 60 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Scott Tannas | M | 62 | 3 ans | |
| Lucile Ribot | F | 57 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Pierre de Villeméjane | M | 56 |
École des Hautes Études Commerciales de Paris
| 3 ans |
| Pascal Cagni | M | 62 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Gaurav Aggarwal | M | 51 | 2 ans | |
| David Drutz | M | 86 | 10 ans | |
| Carole Walter | F | 55 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Eric Marcel Xavier Pichet | M | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Eric Berthelot | M | 63 |
École des Hautes Études Commerciales de Paris
| 2 ans |
| Jean d'Arthuys | M | 57 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Lise Nobre | F | 58 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Martine George | M | 76 |
Université Paris 1 Panthéon-Sorbonne
| 3 ans |
| Pierre François Mellinger | M | 69 |
Université Paris 1 Panthéon-Sorbonne
| 2 ans |
| Xavier Rene Louise Girre | M | 55 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Yves Marque | M | 57 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Odile Roujol | M | - |
École des Hautes Études Commerciales de Paris
| 3 ans |
| Frédéric Lemoine | M | 59 |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Arnaud Raimon | M | 60 |
École des Hautes Études Commerciales de Paris
| 3 ans |
| Carl Nicolino | M | - |
Allostera Pharma, Inc.
Allostera Pharma, Inc. Medical DistributorsDistribution Services Allostera Pharma Inc. is a biopharmaceutical company that has developed an entirely new class of drugs, called Allosteramers™. Allosteramers™ have three main properties: 1) they are “allosteric”, meaning they do not bind to the same site as traditional drugs, potentially providing better safety, efficacy and an entirely new set of patentable intellectual properties, 2) they can have predictable and consistent drug properties, and 3) they are designed to be orally available. Using its Module X technology platform, Allostera has developed a pipeline of seven novel Allosteramers™ against different targets primarily focused on inflammation and autoimmunity including APG2305, a drug inhibiting the IL23 receptor, one of the most important targets in the autoimmune disease field. APG2305 has demonstrated oral activity in animal models of autoimmune diseases. | - |
| Laurent Boissel | M | - |
École des Hautes Études Commerciales de Paris
| 4 ans |
| Olivier Sevillia | M | - |
École des Hautes Études Commerciales de Paris
| 3 ans |
| Jacques van Zuylen | M | - |
École des Hautes Études Commerciales de Paris
| 6 ans |
| Bernadette Clavier | F | - |
École des Hautes Études Commerciales de Paris
| 3 ans |
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| France | 50 | 50,51% |
| Etats-Unis | 28 | 28,28% |
| Canada | 21 | 21,21% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jean-Paul Castaigne
- Réseau Personnel
